However, we demonstrated that targeting PRMT5 induced PD-L1 expression in cancer cells, and it compromised CD8 T cell antitumor immune responses in immunocompetent mice, suggesting that PRMT5 inhibition may have different effects on the immune cell functions in different tumor types. The gene discussed is CD8A; the disease is cancer.